Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Recent & Breaking News (TSXV:TLT)

Virtual Conference for Life Sciences Companies Broadcast Live December 17th, 2020

GlobeNewswire December 14, 2020

University of British Columbia Launched as Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

Accesswire December 7, 2020

CORRECTION: Theralase Releases 3Q2020 Financial Statements

Accesswire November 27, 2020

Theralase Release 3Q2020 Financial Statements

Accesswire November 27, 2020

Theralase Granted FDA Fast Track Designation for NMIBC Phase II Clinical Study

Accesswire November 23, 2020

IIROC Trading Resumption - TLT

Canada NewsWire November 13, 2020

Theralase Technology Demonstrates High Kill Rate of Coronavirus (BSL-2)

Accesswire November 13, 2020

IIROC Trading Halt - TLT

Canada NewsWire November 13, 2020

Theralase Releases Quarterly Newsletter

Accesswire October 26, 2020

Theralase Announces Warrant Extension

Accesswire September 30, 2020

Theralase Provides Update on Bladder Cancer Study

Accesswire September 24, 2020

Theralase Provides Update on Voting Procedures for Shareholder Meeting

Accesswire September 24, 2020

Theralase Release 2Q2020 Financial Statements

Accesswire August 28, 2020

Theralase Amends the Company's Standard By-Laws

Accesswire August 19, 2020

Theralase Signs Agreement with University of Manitoba to Commence Development of Coronavirus Vaccine and Therapy

Accesswire August 19, 2020

Theralase Releases Quarterly Newsletter

Accesswire August 17, 2020

Canadian Clinical Study Sites Re-Commence Bladder Cancer Study

Accesswire August 12, 2020

Theralase Reports on Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study ("Study II") Progress

Accesswire July 30, 2020

Theralase Announces Management Information Circular and Annual General Meeting Postponement Due to COVID-19

Accesswire June 30, 2020

The Top Healthcare Bullboards: April - June 2020

Stockhouse Editorial June 17, 2020